

If you purchased the pharmaceutical
Clobetasol directly from Actavis Holdco
U.S. Inc.; Akorn, Inc.; Fougera
Pharmaceuticals Inc.; Hi-Tech Pharmacal
Co. Inc.; Sandoz, Inc; Morton Grove
Pharmaceuticals, Inc.; Taro
Pharmaceuticals U.S.A. Inc.; or Wockhardt
USA LLC at any time from June 3, 2014 to
December 31, 2018,

Or

If you purchased the pharmaceutical
Clomipramine directly from Mylan Inc.;
Mylan Pharmaceuticals, Inc.; Sandoz, Inc.;
or Taro Pharmaceuticals U.S.A., Inc. at
any time from May 1, 2013 to December 31,
2018, a class action lawsuit could affect
your rights.

A federal court authorized this notice. This is not a solicitation from a lawyer.

- The purpose of this notice is to alert you of Class Action Lawsuits (the “Lawsuits”) brought by Direct Purchasers of Clobetasol and Direct Purchasers of Clomipramine (“Direct Purchaser Plaintiffs” or “DPPs”). The Lawsuits concern two pharmaceuticals and are part of a group of direct purchaser class actions coordinated under the civil docket *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa). There are two lawsuits that are the subject of this notice – one concerns Clobetasol, and one concerns Clomipramine. The Lawsuits each claim that generic drug manufacturers violated antitrust laws, harming competition and causing Class Members to overpay for the products.
- The DPPs bring the Clobetasol Lawsuit against Actavis Holdco U.S. Inc.; Akorn, Inc.; Fougere Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A. Inc.; and Wockhardt USA LLC (“Clobetasol Defendants”).
- The DPPs bring the Clomipramine Lawsuit against Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A., Inc. (“Clomipramine Defendants”).
- Some Defendants, Fougere Pharmaceuticals Inc; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A. Inc., have settled the claims against them in the DPPs’ coordinated actions; you have already received notice of those settlements. While they are no longer Defendants in the Lawsuits, the DPPs continue to seek damages for their sales of Clobetasol and/or Clomipramine from the remaining Defendants. All Defendants deny liability as alleged in the Lawsuits and deny that any Class member is entitled to damages or other relief.
- The Court has approved the Lawsuits between Direct Purchaser Plaintiffs and Defendants to proceed as class actions because they meet the requirements of Federal Rule of Civil Procedure 23, which governs class actions in federal courts. The two certified classes (hereinafter the “Direct Purchaser Classes” or the “Classes”) include:

For Clobetasol:

All persons or entities that directly purchased clobetasol (generic clobetasol propionate topical ointment .05% (15, 30, 45, or 60 gm), topical solution .05% (25 or 50 ml), topical gel .05% (15, 30, or 60 gm), topical cream .05% (15, 30, 45, or 60 gm), or topical emollient cream .05% (15, 30, or 60 gm)) from one or more of the Clobetasol Defendants in the United States and its territories and possessions at any time during the period from June 3, 2014 through December 31, 2018 (the “Clobetasol Class Period”). Excluded from the Clobetasol Class are (a) the Defendants and former defendants [] and their officers, directors, management, employees, subsidiaries, or affiliates, (b) judicial officers and their personnel, (c) all governmental entities, and (d) all persons or entities that (i) purchased at least one form of clobetasol (i.e., ointment, topical solution, topical gel, topical cream, or topical emollient cream) during the period May 15, 2013 to May 14, 2014 (“Clobetasol Pre Period”) and at least one of the same forms during the Clobetasol Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the form(s) purchased in both Periods did not increase

during the Clobetasol Class Period as compared to the Clobetasol Pre Period. (“Clobetasol Class”)

For Clomipramine:

All persons or entities that directly purchased clomipramine (generic clomipramine hydrochloride 25, 50, or 75mg capsules) from one or more of the Clomipramine Defendants in the United States and its territories and possessions at any time during the period from May 1, 2013 through December 31, 2018 (the “Clomipramine Class Period”). Excluded from the Clomipramine Class are (a) the Defendants or former defendants [] and their officers, directors, management, employees, subsidiaries, or affiliates, (b) judicial officers and their personnel, (c) all governmental entities, and (d) all persons or entities that (i) purchased at least one strength of clomipramine (i.e., 25, 50, or 75mg capsules) during the period March 18, 2012 to March 17, 2013 (“Clomipramine Pre Period”) and at least one of the same strengths during the Clomipramine Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the strength(s) purchased in both Periods did not increase during the Clomipramine Class Period as compared to the Clomipramine PrePeriod. (“Clomipramine Class”)

- Each class has a unique class definition and involves unique claims and defenses. Defendants and class representatives, with some exceptions, differ between the two classes. Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.
- You may be a member of the Clobetasol Class, the Clomipramine Class, both classes, or neither class.
- There has been no determination by the Court or a jury that DPPs have sufficiently proven their allegations against the Defendants or that, if proven, the conduct caused harm to any Class Members. Defendants have filed motions for summary judgment, that, if granted, may resolve one or both Lawsuits in their favor. Neither the Court nor a jury has decided who is right. There is no money available now and no guarantee there will be. However, your rights are affected and you have a choice to make now.

YOUR LEGAL RIGHTS ARE AFFECTED WHETHER YOU ACT OR DO NOT ACT,
SO PLEASE READ THIS NOTICE CAREFULLY

YOUR LEGAL RIGHTS AND OPTIONS	
DO NOTHING	By doing nothing, you remain in the Direct Purchaser Classes and may be entitled to share in any recovery that may come from a trial or settlement with Defendants. All the Court's orders will apply to you and legally bind you. You will not be able to start another lawsuit, continue another lawsuit, or be part of any other lawsuit against Defendants about the legal and factual issues in the Clobetasol or Clomipramine cases.
EXCLUDE YOURSELF FROM THE CLASSES	You may choose to exclude yourself, or "opt-out," from one or both of the Direct Purchaser Classes. If you choose to exclude yourself, you will not be bound by any decision in the Lawsuit from which you exclude yourself. This is the only option that allows you to ever be part of any lawsuit (other than these Lawsuits) against the Defendants about these legal claims against the Defendants with respect to your purchases of Clobetasol or Clomipramine.
GET MORE INFORMATION	If you would like to obtain more information about the Lawsuits, you can send questions to the lawyers identified in this notice.

*These rights and options – **and the deadlines to exercise them** – are explained in this notice.*

TABLE OF CONTENTS

WHAT THIS NOTICE CONTAINS

BASIC INFORMATION	PAGE 6
1. Why did I get this notice?	PAGE 6
2. What are these lawsuits about?	PAGE 6
3. What is a class action?	PAGE 7
4. Has the Court identified Class claims, issues, or defenses?	PAGE 7
5. What are the DPPs asking for?	PAGE 7
6. Is there additional money available now?	PAGE 7
WHO IS IN THE DIRECT PURCHASER CLASSES	PAGE 8
7. Am I part of the Clobetasol Class and/or the Clomipramine Class?	PAGE 8
EXCLUDING YOURSELF FROM THE DIRECT PURCHASER CLASSES	PAGE 9
8. Can I get out of the Lawsuits?	PAGE 9
9. If I excluded myself from the previous settlements, am I still part of the Direct Purchaser Classes?	PAGE 9
THE LAWYERS REPRESENTING THE CLASSES	PAGE 10
10. Do I have a lawyer in these cases?	PAGE 10
11. Should I get my own lawyer?	PAGE 10
12. How will the lawyers be paid?	PAGE 10
POTENTIAL TRIAL(S)	PAGE 11
13. How and when will the Court decide who is right?	PAGE 11
14. Do I have to come to trial, if any occur?	PAGE 11
IF YOU DO NOTHING	PAGE 11
15. What happens if I do nothing at all?	PAGE 11
GETTING MORE INFORMATION	PAGE 12
16. How do I get more information?	PAGE 12

BASIC INFORMATION

1. WHY DID I GET THIS NOTICE?

You received this notice because, according to available data and documents, you may have purchased Clobetasol and/or Clomipramine directly from one or more generic manufacturer Defendants during one or both of the class periods:

For Clobetasol, from June 3, 2014 through December 31, 2018, from Actavis Holdco U.S. Inc.; Akorn, Inc.; Fougere Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc.; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A. Inc.; and/or Wockhardt USA LLC.

For Clomipramine, May 1, 2013 through December 31, 2018, from Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and/or Taro Pharmaceuticals U.S.A., Inc.

Therefore, you may be a member of one or both of the Direct Purchaser Classes that were certified by the Court as class actions for purposes of the Lawsuits against the Defendants. This means that the Lawsuits meet the requirements for class actions. Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.

If you are included in the Clobetasol Class and/or the Clomipramine Class, you have a right to know your rights and options before the Court rules on the merits or holds a trial. This notice explains these rights and options.

2. WHAT ARE THESE LAWSUITS ABOUT?

A federal court has certified two classes (the “Clobetasol Class” and the “Clomipramine Class”) in two class action lawsuits brought by Direct Purchasers in *In re: Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724. DPPs’ class action complaints are available at www.GenericDrugDirectClasses.com. Judge Cynthia M. Rufe, of the United States District Court for the Eastern District of Pennsylvania (the “Court”), is overseeing the Lawsuits.

There are two lawsuits that are the subject of this notice – one concerns Clobetasol, and one concerns Clomipramine. In each, the Direct Purchaser Plaintiffs claim that Defendants engaged in an unlawful scheme or schemes to fix, maintain, and stabilize prices, of generic drugs in violation of federal antitrust laws. DPPs allege that this harmed competition and caused Class Members to overpay for Clobetasol and Clomipramine.

All Defendants, including the settling defendants, deny that any Class Member is entitled to damages or other relief. All Defendants deny liability as alleged in the Lawsuits and deny that any Class member is entitled to damages or other relief.

There has been no determination by the Court or a jury that the allegations against the Defendants have been proven or that, if proven, the conduct caused harm to any Class Members. No trial has been held. Defendants have filed motions for summary judgment, that, if granted, may resolve one or both Lawsuits in their favor.

Neither the Court nor a jury has decided whether DPPs have sufficiently proved that any defendant violated any laws. This notice is not an expression of any opinion by the Court as to

the merits of Direct Purchaser Plaintiffs' claims against any Defendant or the defenses asserted by any Defendant.

3. WHAT IS A CLASS ACTION?

In a class action, one or more people called “Class Representatives” sue on behalf of others who have similar claims.

In this case, the Court appointed César Castillo, LLC; FWK Holdings, LLC; Rochester Drug Co-Operative, Inc.; and KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. as class representatives for the Clobetasol Class. The Court appointed FWK Holdings, LLC; Rochester Drug Co-Operative, Inc.; and KPH Healthcare Services, Inc. a/k/a Kinney Drugs, Inc. as Class Representatives for the Clomipramine Class.

The Class Representatives and the entities on whose behalf they have sued together constitute the “Class” or “Class Members.” They are also called the “Direct Purchaser Plaintiffs.” Their attorneys are called “Plaintiffs’ Counsel,” “Lead Counsel for the Class,” or “Class Counsel.”

In a class action lawsuit, one court resolves the issues for all Class Members, except for those who exclude themselves (i.e., “opt out”) from the Class. The District Court, by opinion and order filed on March 7, 2025, has determined that the Lawsuits by Direct Purchaser Plaintiffs against the Defendants can proceed as class actions. Copies of the Court’s order and opinion may be found at www.GenericDrugDirectClasses.com.

Defendants filed petitions for permission to appeal the orders certifying the classes; it is possible that one or both classes may be modified or decertified.

4. HAS THE COURT IDENTIFIED CLASS CLAIMS, ISSUES, OR DEFENSES?

The Court has ordered that all Clobetasol and Clomipramine claims and defenses shall proceed as class actions. DPPs allege Defendants violated Section 1 of the Sherman Antitrust Act. Section 1 prohibits agreements between competitors that unreasonably restrain interstate commerce.

5. WHAT ARE THE DPPs ASKING FOR?

Plaintiffs are asking for money for the Direct Purchaser Classes from the remaining Defendants who have not settled.

6. IS THERE ADDITIONAL MONEY AVAILABLE NOW?

No. Previously, some Defendants settled the claims against them in the DPPs’ coordinated actions. You received notice of those settlements.

However, no additional money is available now because the Court and/or jury has not yet decided whether the remaining Defendants did anything wrong, and the DPPs and the remaining Defendants have not settled the case. There is no guarantee that money or benefits will ever be obtained. If they are, you will be notified.

WHO IS IN THE DIRECT PURCHASER CLASSES

7. AM I PART OF THE CLOBETASOL CLASS AND/OR THE CLOMIPRAMINE CLASS?

You are part of the Clobetasol Class if you are a person or entity in the United States and its territories that purchased Clobetasol from one or more Current or Former Defendants (Actavis Holdco U.S.A. Inc.; Akorn, Inc.; Fougere Pharmaceuticals Inc.; Hi-Tech Pharmacal Co. Inc.; Sandoz, Inc.; Morton Grove Pharmaceuticals, Inc.; Taro Pharmaceuticals U.S.A. Inc.; and Wockhardt USA LLC) at any time from June 3, 2014 through December 31, 2018.

Excluded from the Clobetasol Class are:

Current or Former Defendants and their officers, directors, management, employees, subsidiaries, or affiliates; judicial officers and their personnel; all government entities; and,

All persons or entities that (i) purchased at least one form of clobetasol (i.e., ointment, topical solution, topical gel, topical cream, or topical emollient cream) during the period May 15, 2013 to May 14, 2014 (“Clobetasol Pre Period”) and at least one of the same forms during the Clobetasol Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the form(s) purchased in both Periods did not increase during the Clobetasol Class Period as compared to the Clobetasol Pre Period.

You are part of the Clomipramine Class if you are a person or entity in the United States and its territories that purchased Clomipramine from one or more Current or Former Defendants (Mylan Inc.; Mylan Pharmaceuticals, Inc.; Sandoz, Inc.; and Taro Pharmaceuticals U.S.A., Inc.) at any time from and/or May 1, 2013 through December 31, 2018.

Excluded from the Clomipramine Class are:

Current or Former Defendants and their officers, directors, management, employees, subsidiaries, or affiliates; judicial officers and their personnel; all government entities; and,

All persons or entities that (i) purchased at least one strength of clomipramine (i.e., 25, 50, or 75mg capsules) during the period March 18, 2012 to March 17, 2013 (“Clomipramine Pre Period”) and at least one of the same strengths during the Clomipramine Class Period and (ii) whose purchase prices (measured in dollars and cents) for all of the strength(s) purchased in both Periods did not increase during the Clomipramine Class Period as compared to the Clomipramine PrePeriod.

You may be a member of the Clobetasol Class, the Clomipramine Class, both classes, or neither class. A list of National Drug Codes (“NDCs”) for Clobetasol and Clomipramine are available at www.GenericDrugDirectClasses.com.

If you are not sure whether you are included in the Clobetasol Class and/or the Clomipramine Class, you may call or write to the lawyers in this case at the telephone numbers or addresses listed in Question 10 below. If you wish to exclude yourself from one or more of these Classes, please see Question 8.

EXCLUDING YOURSELF FROM THE DIRECT PURCHASER CLASSES

8. CAN I GET OUT OF THE LAWSUITS?

Yes, if you exclude yourself from the Clobetasol Class, the Clomipramine Class, or both of the Direct Purchaser Classes, or “opt out,” on or before July 1, 2025, 60 days from the date this notice is mailed (May 2, 2025).

If you are a member of both classes, you may exclude yourself from one class, both classes, or neither class.

To exclude yourself, you must send a letter via first class U.S. mail *or* by email (though we recommend you do both) saying you want to exclude yourself from one or both Direct Purchaser Class Actions in *In re Generic Pharmaceuticals Pricing Antitrust Litigation*, No. 2:16-MD-02724 (E.D. Pa.). Please specify if you wish to exclude yourself from the Clobetasol Class Action, the Clomipramine Class Action, or both the Clobetasol Class and the Clomipramine Class. Be sure to include your name, address, email address, telephone number, and your signature.

Your letter or email requesting exclusion must be postmarked/sent no later than July 1, 2025.

Mail the letter to: *In re: Generic Pharmaceuticals Pricing Antitrust Litigation* – Direct Purchasers, c/o A.B. Data, Ltd., P.O. Box 173095, Milwaukee, WI 53217.

Send email to: info@GenericDrugDirectClasses.com.

If your right to recover stems from your own qualifying purchases of Clobetasol or Clomipramine, no more is required of you.

If you exclude yourself from one or both classes, you will not be legally bound by anything that happens in the Lawsuits between DPPs and the Defendants concerning Clobetasol and/or Clomipramine. This means that you may be able to sue (or continue to sue) the Defendants in the future about the legal issues in these cases involving Clobetasol and/or Clomipramine. If you exclude yourself from the Class(es) so that you can start or continue your own lawsuit against one or more of the Defendants, you should talk to your own lawyer immediately because your claims will be subject to a statute of limitations, which means that your claims will expire if you do not take timely action. **You need to contact your own lawyer about this issue.**

If you do not exclude yourself from the class(es), you will keep the right to a share of any recovery that may come from a trial or settlement of the Lawsuit(s) against Defendants. You will not be able to start another lawsuit, continue another lawsuit, or be part of any other lawsuit against Defendants about the legal issues involving Clobetasol and/or Clomipramine in these Lawsuits regardless of whether there is a recovery. All the Court’s orders in the case(s) by the Direct Purchaser Plaintiffs against Defendants will apply to you and legally bind you. You will also be bound by any judgment in the Lawsuit(s).

9. IF I EXCLUDED MYSELF FROM THE PREVIOUS SETTLEMENTS, AM I STILL PART OF THE DIRECT PURCHASER CLASSES?

Yes. If you are a member of the Clobetasol Class, the Clomipramine Class, or both Direct Purchaser Classes, even if you excluded yourself from the previous settlements, you will still be part of the Direct Purchaser Classes in these Lawsuits unless you exclude yourself now (see Question 8).

THE LAWYERS REPRESENTING THE CLASSES

10. DO I HAVE A LAWYER IN THESE CASES?

The Court appointed the counsel listed below as Class Counsel:

Dianne M. Nast, Esq. Joseph N. Roda, Esq. NASTLAW LLC 1101 Market Street, Suite 2801 Philadelphia, Pennsylvania 19107 215-923-9300 dnast@nastlaw.com jnroda@nastlaw.com	David F. Sorensen, Esq. BERGER MONTAGUE PC 1818 Market Street, Suite 3600 Philadelphia, PA 19103 (215) 875-3000 dsorensen@bm.net
Robert N. Kaplan KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue New York, New York 10022 (212) 687-1980 rkaplan@kaplanfox.com	Thomas M. Sobol, Esq. HAGENS BERMAN SOBOL SHAPIRO LLP 1 Faneuil Hall Square, 5th Floor Boston, Massachusetts 02109 (617) 482-3700 tom@hbsslaw.com
Linda P. Nussbaum NUSSBAUM LAW GROUP, PC 1133 Avenue of the Americas, 31st Floor New York, New York 10036 (917) 438-9189 lnussbaum@nussbaumpc.com	Michael L. Roberts ROBERTS LAW FIRM P.A. 1920 McKinney Ave., Suite 700 Dallas, Texas 75201 (501) 821-5575 mikeroberts@robertslawfirm.us

11. SHOULD I GET MY OWN LAWYER?

The Court has appointed the attorneys above to represent the classes as “Class Counsel.” You don’t have to pay Class Counsel or anyone else to participate or to opt out. You may hire your own lawyer to appear in Court for you, but if you do, you may retain that lawyer at your own expense.

12. HOW WILL THE LAWYERS BE PAID?

If Class Counsel achieves a recovery for a Class, for example by way of settlement or after winning at trial, the Court will be asked to approve reasonable attorneys’ fees, as well as reimbursement of expenses Class Counsel have advanced on behalf of that Class. If the Court grants Class Counsel’s requests, fees and expenses would either be deducted from any money obtained for that Class, or the Court may order the Defendants to pay attorneys’ fees and costs in addition to any damage award to that Class. Members of that Class will not have to pay any attorneys’ fees or expenses except out of money obtained for that Class.

POTENTIAL TRIAL(S)

13. HOW AND WHEN WILL THE COURT DECIDE WHO IS RIGHT?

Defendants have filed motions for summary judgment, that, if granted, may resolve one or both matters in their favor. If the claims against Defendants are not resolved by motion, settlement, or otherwise, Class Counsel will have to prove DPPs' claims at trial. A jury trial is scheduled for August 4, 2025, but the Court has not yet determined whether the trial will include DPPs' claims or relate to Clobetasol or Clomipramine. Each product will be the subject of a separate trial, if any trials occur. There is no guarantee that Direct Purchaser Plaintiffs will win either trial, or that they will get any money for the Direct Purchaser Classes. The trials, if any, will take place at the United States District Court for the Eastern District of Pennsylvania, James A. Byrne U.S. Courthouse, 601 Market Street, Philadelphia, PA 19106 before the Honorable Cynthia M. Rufe. There is no guarantee that DPPs will win, or that they will get any money for the Direct Purchaser Classes. Any judgment will be binding on all members of the Direct Purchaser Classes who have not opted out, regardless of who wins.

14. DO I HAVE TO COME TO THE TRIALS, IF ANY OCCUR?

You do not need to attend the trials, if any occur. Class Counsel will present the case for Direct Purchaser Class Plaintiffs and the Direct Purchaser Classes, and counsel for Defendants will present Defendants' defenses. You and/or your own lawyer are welcome to attend the trials, if any occur, at your own expense. If Direct Purchaser Plaintiffs obtain money as a result of a trial or settlement, you will be notified about how to participate. We do not know how long this will take. Important information about the cases will be posted on the website www.GenericDrugDirectClasses.com as it becomes available.

IF YOU DO NOTHING

15. WHAT HAPPENS IF I DO NOTHING AT ALL?

If you do nothing, you will keep the right to a share of any recovery that may come from a trial or settlement of these Lawsuits against Defendants. There may be no recovery at all. You will not be able to start another lawsuit, continue another lawsuit, or be part of any other lawsuit against Defendants about the legal and factual issues in these cases. All the Court's orders in the case(s) by the DPPs against Defendants will apply to you and legally bind you. You will also be bound by any judgment in the Lawsuit(s).

GETTING MORE INFORMATION

16. HOW DO I GET MORE INFORMATION?

If you have questions about these cases or want additional information, you may call or write to the lawyers listed in answer to Question 10 above, call 877-315-0583, or visit www.GenericDrugDirectClasses.com. You may also view selected filings from the litigation on the Court's PACER system or inspect the papers on public file with the United States District Court for the Eastern District of Pennsylvania, 601 Market Street, Philadelphia, PA 19106. Selected filings are available at: www.GenericDrugDirectClasses.com.

PLEASE DO NOT TELEPHONE THE COURT OR THE COURT CLERK'S OFFICE FOR INFORMATION.

DATE: May 2, 2025

BY THE COURT

Honorable Cynthia M. Rufe
United States District Judge
Eastern District of Pennsylvania